Commentary of updates to the 5th international consensus guidelines for breast cancer in young women

doi:10.3877/cma.j.issn.1674-0807.2023.02.001

Abstract

Abstract:

Breast cancer has surpassed lung cancer as the most commonly diagnosed cancer, with the highest incidence and mortality among cancers in females. Compared with Western countries, the proportion of young breast cancer patients in China is relatively higher. In the diagnosis and treatment of young breast cancer patients, the clinicians should take the following characteristics into account: high proportion of triple negative breast cancer and, advanced tumor grade, high rate of HER-2 over-expression and proneness to recurrence and poor prognosis. In August 2020, the European School of Oncology and the European Society of Medical Oncology issued the 5th international consensus guidelines for breast cancer in young women (BCY5). In this article, we interpreted the updates on breast cancer diagnosis, treatment and follow-up in the BCY5 in combination with other guidelines in China and abroad, so as to provide a reference for clinicians.

Key words: Breast neoplasms, Femininity, lines

Kailin Wang, Shunying Li, Qiang Liu. Commentary of updates to the 5th international consensus guidelines for breast cancer in young women[J]. Chinese Journal of Breast Disease(Electronic Edition), 2023, 17(02): 65-71.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhrxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0807.2023.02.001

https://zhrxbzz.cma-cmc.com.cn/EN/Y2023/V17/I02/65

Figures/Tables 1

References 54

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2]	Daly AA, Rolph R, Cutress RI, et al. A review of modifiable risk factors in young women for the prevention of breast cancer [J]. Breast Cancer (Dove Med Press), 2021, 13: 241-257.
[3]	Paluch SS, Cardoso F, Partridge AH, et al. ESO-ESMO fifth international consensus guidelines for breast cancer in young women (BCY5) [J]. Ann Oncol, 2022, 33(11): 1097-1118.
[4]	Fan L, Strasser WK, Li JJ, et al. Breast cancer in China [J]. Lancet Oncol, 2014, 15(7): e279-289.
[5]	陈万青，郑荣寿. 中国女性乳腺癌发病死亡和生存状况 [J]. 中国肿瘤临床，2015, 42(13): 668-674.
[6]	林锦娜，刘强. 第4版《年轻女性乳腺癌国际共识指南》更新要点解读 [J/CD]. 中华乳腺病杂志(电子版), 2021，15(4): 6.
[7]	Paluch SS, Cardoso F, Partridge AH, et al. ESO-ESMO fifth international consensus guidelines for breast cancer in young women (BCY5) [J]. Ann Oncol, 2022; 33(11)：1097-1118.
[8]	中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2021年版) [J]. 中国癌症杂志，2021, 31(10)：954-1040.
[9]	孙正魁，江泽飞.2022版《中国临床肿瘤学会乳腺癌诊疗指南》更新解读[J]．中国肿瘤外科杂志，2022，14(3)：212-218.
[10]	Azim HA Jr, Partridge AH. Biology of breast cancer in young women [J]. Breast Cancer Res, 2014, 16(4): 427.
[11]	Liao S, Hartmaier RJ, McGuire KP, et al. The molecular landscape of premenopausal breast cancer [J]. Breast Cancer Res, 2015, 17: 104.
[12]	Barroso SR, Jain E, Cohen O, et al. Prevalence and mutational determinants of high tumor mutation burden in breast cancer [J]. Ann Oncol, 2020, 31(3): 387-394.
[13]	Daly MB, Pal T, Berry MP, et al. Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology [J]. J Natl Compr Canc Netw, 2021, 19(1): 77-102.
[14]	Regan MM, Francis PA, Pagani O, et al. Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT trials [J]. J Clin Oncol, 2016, 34(19): 2221-2231.
[15]	Kim HA, Lee JW, Nam SJ, et al. Adding ovarian suppression to tamoxifen for premenopausal breast cancer: a randomized phase Ⅲ trial [J]. J Clin Oncol, 2020, 38(5): 434-443.
[16]	Premenopausal Breast Cancer Collaborative Group, Schoemaker MJ, Nichols HB, et al. Association of body mass index and age with subsequent breast cancer risk in premenopausal women [J]. JAMA Oncol, 2018, 4(11): e181771.
[17]	Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study [J]. J Natl Cancer Inst, 2005, 97(22): 1652-1662.
[18]	DeCensi A, Puntoni M, Guerrieri GA, et al. Randomized placebo controlled trial of low-dose tamoxifen to prevent local and contralateral recurrence in breast intraepithelial neoplasia [J]. J Clin Oncol, 2019, 37(19): 1629-1637.
[19]	Sutherland N, Espinel W, Grotzke M, et al. Unanswered questions: hereditary breast and gynecological cancer risk assessment in transgender adolescents and young adults [J]. J Genet Couns, 2020, 29(4): 625-633.
[20]	Kratz CP, Achatz MI, Brugieres L, et al. Cancer screening recommendations for individuals with Li-Fraumeni syndrome [J]. Clin Cancer Res, 2017, 23(11): e38-e45.
[21]	Chong A, Weinstein SP, McDonald ES, et al. Digital breast tomosynthesis: concepts and clinical practice [J]. Radiology, 2019, 292(1): 1-14.
[22]	Sechopoulos I, Teuwen J, Mann R. Artificial intelligence for breast cancer detection in mammography and digital breast tomosynthesis: State of the art [J]. Semin Cancer Biol, 2021, 72: 214-225.
[23]	Wong SM, Freedman RA, Sagara Y, et al. Growing use of contralateral prophylactic mastectomy despite no improvement in long-term survival for invasive breast cancer [J]. Ann Surg, 2017, 265(3): 581-589.
[24]	Findlay SL, Lima I, Smith G, et al. Canada follows the US in the rise of bilateral mastectomies for unilateral breast cancer: a 23-year population cohort study [J]. Breast Cancer Res Treat, 2021, 185(2): 517-525.
[25]	Sella T, Snow C, Freeman H, et al. Young, empowered and strong: a web-based education and supportive care intervention for young women with breast cancer across the care continuum [J]. JCO Clin Cancer Inform, 2021, 5: 933-943.
[26]	King MT, Link EK, Whelan TJ, et al. Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial [J]. Lancet Oncol, 2020, 21(5): 685-698.
[27]	Francis PA, Pagani O, Fleming GF, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer [J]. N Engl J Med, 2018, 379(2): 122-137.
[28]	Pagani O, Francis PA, Fleming GF, et al. Absolute improvements in freedom from distant recurrence to tailor adjuvant endocrine therapies for premenopausal women: Results from TEXT and SOFT [J]. J Clin Oncol, 2020, 38(12): 1293-1303.
[29]	Boccardo F, Rubagotti A, Amoroso D, et al. Endocrinological and clinical evaluation of two depot formulations of leuprolide acetate in pre- and perimenopausal breast cancer patients [J]. Cancer Chemother Pharmacol, 1999, 43(6): 461-466.
[30]	Noguchi S, Kim HJ, Jesena A, et al. Phase 3, open-label, randomized study comparing 3-monthly with monthly goserelin in pre-menopausal women with estrogen receptor-positive advanced breast cancer [J]. Breast Cancer, 2016, 23(5): 771-779.
[31]	Lee YJ, Wu ZY, Kim HJ, et al. Change in estradiol levels among premenopausal patients with breast cancer treated using leuprolide acetate 11.25 milligrams 3-month depot and tamoxifen [J]. J Breast Cancer, 2020, 23(5): 553-559.
[32]	Masuda N, Iwata H, Rai Y, et al. Monthly versus 3-monthly goserelin acetate treatment in pre-menopausal patients with estrogen receptor-positive early breast cancer [J]. Breast Cancer Res Treat, 2011, 126(2): 443-451.
[33]	Aydiner A, Kilic L, Yildiz I, et al. Two different formulations with equivalent effect? Comparison of serum estradiol suppression with monthly goserelin and trimonthly leuprolide in breast cancer patients [J]. Med Oncol, 2013, 30(1): 354.
[34]	Schmid P, Untch M, Kossé V, et al. Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study [J]. J Clin Oncol, 2007, 25(18): 2509-2515.
[35]	Kurebayashi J, Toyama T, Sumino S, et al. Efficacy and safety of leuprorelin acetate 6-month depot, TAP-144-SR (6M), in combination with tamoxifen in postoperative, premenopausal patients with hormone receptor-positive breast cancer: a phase Ⅲ，randomized, open-label, parallel-group comparative study [J]. Breast Cancer, 2017, 24(1): 161-170.
[36]	陈祎霏，严颖，姜晗昉，等．促性腺激素释放激素激动剂对绝经前激素受体阳性乳腺癌患者去势效果分析——真实世界研究[J]．军事医学，2021，45(5)：373-379.
[37]	Perrone F, De Laurentiis M, De Placido S, et al. Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial [J]. Eur J Cancer, 2019, 118: 178-186.
[38]	Mayer EL, Dueck AC, Martin M, et al. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study [J]. Lancet Oncol, 2021, 22(2): 212-222.
[39]	Loibl S, Marme F, Martin M, et al. Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer-the Penelope-B Trial [J]. J Clin Oncol, 2021, 39(14): 1518-1530.
[40]	Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+，HER2-，node-positive, high-risk, early breast cancer (monarchE) [J]. J Clin Oncol, 2020, 38(34): 3987-3998.
[41]	Oktay K, Harvey BE, Loren AW. Fertility preservation in patients with cancer: ASCO clinical practice guideline update summary [J]. J Oncol Pract, 2018, 14(6): 381-385.
[42]	Leonard R, Yellowlees A, Mansi J, et al. The affect of goserelin on the QoL of women having chemotherapy for EBC: Results from the OPTION trial [J]. Breast, 2020, 52: 122-131.
[43]	Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast Cancer [J]. N Engl J Med, 2022, 386(6): 556-567.
[44]	Mittendorf EA, Zhang H, Barrios CH, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial [J]. The Lancet, 2020, 396(10 257): 1090-1100.
[45]	Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer [J]. N Engl J Med, 2021, 384(25): 2394-2405.
[46]	Partridge AH, Gelber S, Piccart GMJ, et al. Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial [J]. J Clin Oncol, 2013, 31(21): 2692-2698.
[47]	Chan A, Moy B, Mansi J, et al. Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the phase Ⅲ ExteNET trial [J]. Clin Breast Cancer, 2021, 21(1): 80-91.
[48]	Robson ME, Tung N, Conte P, et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer [J]. Ann Oncol, 2019, 30(4): 558-566.
[49]	Cardoso F, Paluch SS, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) [J]. Ann Oncol, 2020, 31(12): 1623-1649.
[50]	Litton JK, Hurvitz SA, Mina LA, et al. talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial [J]. Ann Oncol, 2020, 31(11): 1526-1535.
[51]	Steenbeek MP, Harmsen MG, Hoogerbrugge N, et al. Association of salpingectomy with delayed oophorectomy versus salpingo-oophorectomy with quality of life in BRCA1/2 pathogenic variant carriers: A nonrandomized controlled trial [J]. JAMA Oncol, 2021, 7(8): 1203-1212.
[52]	Gaba F, Piek J, Menon U, et al. Risk-reducing early salpingectomy and delayed oophorectomy as a two-staged alternative for primary prevention of ovarian cancer in women at increased risk: a commentary [J]. BJOG, 2019, 126(7): 831-839.
[53]	Ahmad S, Fergus K, McCarthy M. Psychosocial issues experienced by young women with breast cancer: the minority group with the majority of need [J]. Curr Opin Support Palliat Care, 2015, 9(3): 271-278.
[54]	Subramani R, Lakshmanaswamy R. Pregnancy and breast cancer [J]. Prog Mol Biol Transl Sci, 2017, 151: 81-111.

分级	内容
证据等级
Ⅰ	至少一项大型随机对照研究(方法学质量高、偏倚性低)或基于无异质性高质量随机对照研究的Meta分析
Ⅱ	小型/大型随机对照研究(方法学质量低、存在偏倚性)或基于前述研究，或存在差异性的Meta分析
Ⅲ	前瞻性队列研究
Ⅳ	回顾性队列研究或病例对照研究
Ⅴ	无对照组的研究、病例报告、专家意见
推荐等级
A	强有力的证据表明其疗效具有实质性的临床获益，强烈推荐
B	强/中等有力的疗效证据，临床获益有限，一般推荐
C	较弱的获益证据或获益小、风险大(如不良事件、成本支出等)，可选
D	对疗效及预后不利的中等级证据，一般不推荐
E	对疗效及预后不利的高等级证据，永不推荐

分级	内容
证据等级
Ⅰ	至少一项大型随机对照研究(方法学质量高、偏倚性低)或基于无异质性高质量随机对照研究的Meta分析
Ⅱ	小型/大型随机对照研究(方法学质量低、存在偏倚性)或基于前述研究，或存在差异性的Meta分析
Ⅲ	前瞻性队列研究
Ⅳ	回顾性队列研究或病例对照研究
Ⅴ	无对照组的研究、病例报告、专家意见
推荐等级
A	强有力的证据表明其疗效具有实质性的临床获益，强烈推荐
B	强/中等有力的疗效证据，临床获益有限，一般推荐
C	较弱的获益证据或获益小、风险大(如不良事件、成本支出等)，可选
D	对疗效及预后不利的中等级证据，一般不推荐
E	对疗效及预后不利的高等级证据，永不推荐

Please choose a citation manager

Content to export